.Pharmacolibrary.Drugs.R_RespiratorySystem.R06A_AntihistaminesForSystemicUse.R06AX24_Epinastine.Epinastine .Pharmacolibrary.Drugs.R_RespiratorySystem.R06A_AntihistaminesForSystemicUse.R06AX24_Epinastine.Epinastine| name: | Epinastine | |
| ATC code: | R06AX24 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 87 | L |
| clearance: | 42 | L/h |
| other parameters in model implementation | ||
Epinastine is a second-generation antihistamine (H1 receptor antagonist) used primarily for the treatment of allergic conjunctivitis and, in some countries, allergic rhinitis. It is approved for topical ophthalmic use and is available in some markets, but not all.
Pharmacokinetic parameters estimated for healthy adult individuals; no peer-reviewed human pharmacokinetic publication was identified at time of report.
Sarashina, A, et al., & Igarashi, T (2005). Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. British journal of clinical pharmacology 59(1) 43–53. DOI:10.1111/j.1365-2125.2005.2250 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15606439
Jang, JH, & Jeong, SH (2025). Population modeling of pharmacokinetic variability of epinastine, a histamine H. Naunyn-Schmiedeberg's archives of pharmacology None –. DOI:10.1007/s00210-025-04299-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40439884